New expensive but disease-modifying treatments are expected to foster Alzheimer’s disease market growth globally, according to a report. The report by GlobalData, a data and analytics company, showed ...

A new study published in the Journal of Neurosurgery highlights the potential of focused ultrasound technology in treating ...

With these key hires, Alpha Cognition is poised to advance its mission of improving the lives of patients and families ...

The Phase Ia trial is designed to assess the safety and efficacy of the company’s drug designed to target chemicals thought to be a cause of Alzheimer’s disease.

Last month, the FDA granted approval to Eli Lilly’s donanemab - or Kisunla - for the treatment of Alzheimer’s disease ... as offering “exciting new options” for patients.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its preliminary* fourth ...

I offered some tips to help reboot your sleep health. That list still contains my top tips. But this year, I want to add to ...

Thought to be one of the drivers behind the development of Alzheimer’s, ProMIS’ PMN310 is designed to target AβO in hopes of slowing disease progression. Credit: Shutterstock / meeboonstudio Canadian ...

Learn how quickly you can expect relief from Klonopin, a benzodiazepine medication commonly prescribed for anxiety and ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Alzheimer’s is the most common form of dementia — it causes memory loss, confusion, thinking problems and behavioral changes.

Most treatments being pursued today to protect against Alzheimer's disease focus on amyloid plaques and tau tangles that ...